7-Oxabicycloheptane substituted aryl amino prostaglandin analogs and their use in inhibiting platelet aggregation and bronchoconstriction
申请人:E.R. Squibb & Sons, Inc.
公开号:EP0201811A1
公开(公告)日:1986-11-20
7-Oxabicycloheptane substituted arylamino prostaglandin analogs are provided having the structural formula
wherein A is -CH=CH- or -(CH2)2-; m is 1 to 8; n is 1 to 5; R is H, lower alkyl, alkali metal or a polyhydroxyamino salt; R' is H, lower alkyl, hydroxyalkyl or aryl; R2 is H, lower alkyl, aryl or cycloalkyl, R3 is substituted aryl wherein the aryl group (which may be phenyl or naphthyl) is substituted with one or two of the following group: hydroxy,
wherein R4 and R5 may be the same or different and are H or lower alkyl, and including all stereoisomers thereof.
The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.
7-oxabicycloheptane substituted aryl amino prostaglandin analogs and
申请人:E. R. Squibb & Sons, Inc.
公开号:US04607048A1
公开(公告)日:1986-08-19
7-Oxabicycloheptane substituted aryl amino prostaglandin analogs are provided having the structural formula ##STR1## wherein A is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --; m is 1 to 8; n is 1 to 5; R is H, lower alkyl, alkali metal or a polyhydroxyamino salt; R.sup.1 is H, lower alkyl, hydroxyalkyl or aryl; R.sup.2 is H, lower alkyl, aryl or cycloalkyl, R.sup.3 is substituted aryl wherein the aryl group (which may be phenyl or naphthyl) is substituted with one or two of the following groups: hydroxy, ##STR2## SR.sup.4, --CN, --NO.sub.2, ##STR3## wherein R.sup.4 and R.sup.5 may be the same or different and are H or lower alkyl, and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.
The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.